Company: DVAX
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001029142-25-000117
Chunk: 281

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 8
Chunk 281
---
79,147 (15,238)Segment income (loss) (3)$18,721 $11,386 $(77,378)$2,665 (1)The significant expense categories and amounts align with the segment-level information that is regularly provided to the CODM.(2)Other segment items includes the net of: bad debt expense, interest income, interest expense, sublease income, loss on debt extinguishment, other expenses, and provision for income taxes, as presented on the face of our condensed consolidated statements of operations.(3)Net income (loss) is our reported measure of segment profit or loss.

9. Revenue Recognition 

Disaggregation of RevenuesThe following table disaggregates our product revenue, net by product and geographic region and disaggregates our other revenues by geographic region (in thousands): Three Months EndedJune 30, 2025Three Months EndedJune 30, 2024 U.S.Non U.S.TotalU.S.Non U.S.TotalProduct revenue, net     HEPLISAV-B$90,250 $1,622 $91,872 $68,988 $1,200 $70,188 Total product revenue, net90,250 1,622 91,872 68,988 1,200 70,188 Other revenue3,317 253 3,570 3,598 9 3,607 Total revenues$93,567 $1,875 $95,442 $72,586 $1,209 $73,795 Six Months EndedJune 30, 2025Six Months EndedJune 30, 2024U.S.Non U.S.TotalU.S.Non U.S.TotalProduct revenue, netHEPLISAV-B$155,209 $1,622 $156,831 $115,685 $2,347 $118,032 Total product revenue, net155,209 1,622 156,831 115,685 2,347 118,032 Other revenue6,164 611 6,775 6,400 152 6,552 Total revenues$161,373 $2,233 $163,606 $122,085 $2,499 $124,584 Revenues from Major Customers and Collaboration PartnersHEPLISAV-B product sales in the U.S. are to certain wholesalers and specialty distributors whose principal customers include